Neuralgia Treatment Market, By Treatment, By End Use, By Country, and By Region – Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

REPORT HIGHLIGHT

Neuralgia Treatment Market size was valued at US$ 2,695.91 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.
Neuralgia treatment is the treatment of a medical condition characterized by chronic pain in the nerves that can be caused by injury, infection, or other medical issues. Neuralgia treatment is used to alleviate symptoms, slow the progression of the condition, and avoid complications.
Neuralgia Treatment Market- Market Dynamics

Growing Prevalence Of Chronic Diseases Fuels Market Growth
The increasing prevalence of chronic diseases, such as diabetes, is expected to drive future growth in the neuralgia treatment market. Chronic diseases are problems that last a year or more and require ongoing medical care, limit daily activities, or both. Diabetes is a chronic metabolic condition characterized by high blood glucose, also known as blood sugar. Neuralgia treatment can help with diabetic neuropathy, which is nerve damage that can occur in people with diabetes. For instance, the World Health Organization, a United Nations specialized agency based in Switzerland, reported 41 million deaths in September 2023, accounting for 74% of all deaths caused by noncommunicable diseases (NCDs) or chronic diseases worldwide.As a result, the increasing prevalence of chronic diseases such as diabetes is driving the growth of the neuralgia treatment market.
Neuralgia Treatment Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2025-2032)
According to treatment segmentation, the year 2025 is expected to see the highest market share for surgery.
According to End Use segmentation, the most common End Use in 2025 will be hospitals and clinics.
North America ranked as the top revenue-generating region in 2025.
Neuralgia Treatment Market- Segmentation Analysis:

The Global Neuralgia Treatment Market is segmented on the basis of Treatment, End Use, and Region.
The market is divided into two categories based on Treatment: Drug Based, and Surgery. The surgery segment will dominate the market in 2025. The growing demand for precise, non-invasive treatment options, such as robotic radiosurgery, is a major driver in the segment. These advanced methods provide targeted pain relief while reducing the need for traditional medications or invasive surgeries. Robotic radiosurgery allows for high accuracy while causing minimal damage to surrounding tissues, which improves patient outcomes. The market is being driven by a shift toward less invasive treatments, as patients seek safer, more effective alternatives.
The market is divided into three categories based on End Use: Hospital & Clinics, Ambulatory Surgery Centers, and Others. In 2025, the hospital and clinics segment will account for the largest market revenue share. Adoption of advanced, non-invasive technologies in hospitals and clinics drives market growth by allowing for more precise and targeted treatments. These technologies reduce the need for invasive procedures, resulting in faster recovery times and less patient discomfort. Healthcare providers can achieve better results with greater precision, increasing overall patient satisfaction. This shift toward less invasive options increases demand for advanced neuralgia treatments.
Neuralgia Treatment Market- Geographical Insights

North America neuralgia treatment market will hold the largest share in 2025 due to the rising prevalence of chronic pain conditions like painful diabetic neuropathy (PDN) among diabetics, driving demand for non-invasive, effective treatments. The FDA approved Neuralace Medical's non-invasive Axon Therapy for painful diabetic neuropathy in January 2024. This approval advances pain management for diabetics with limb nerve pain. Axon Therapy stimulates nerves with low-voltage electrical pulses to reduce pain without drugs or surgery. The therapy may help many diabetics with chronic neuropathic pain by being safer and more accessible.
Asia Pacific neuralgia treatment market to grow fastest over forecast period. Innovative treatment solutions approved by regulators have increased nerve repair surgery options in the region. Orthocell Ltd., a regenerative medicine company, received regulatory approval from Singapore's Health Sciences Authority (HSA) for Remplir, allowing sales to begin in Q1 of CY25. Device Technologies, a well-known medical device supplier, distributed Remplir in Australia and New Zealand before this approval. Remplir collagen wraps improve nerve repair surgery.
Neuralgia Treatment Market- Competitive Landscape:

The Neuralgia Treatment Market is moderately competitive, with Pfizer, GlaxoSmithKline, Novartis, and Biogen dominating the pharmaceutical segment with anticonvulsants, antidepressants, and topical analgesics. The market is seeing more collaboration and mergers, such as Globus Medical's acquisition of Nevro, to expand its neuromodulation offerings. Regional players in Asia-Pacific are also gaining ground as healthcare access improves and therapies become more affordable. Overall, the landscape is shaped by advances in targeted drug therapies, minimally invasive pain management solutions, and the growing use of personalized treatment approaches.

Recent Developments:

In January 2024, Zydus Lifesciences has received final FDA approval for its generic Gabapentin tablets for the treatment of postherpetic neuralgia (PHN). The approval covers 300 mg and 600 mg once-daily doses of a drug used to relieve pain after shingles.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEURALGIA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GSK plc.
Pfizer Inc.
Biogen
Zydus Group (Cadila Healthcare Limited)
H. Lundbeck A/S
Novartis AG
Others

GLOBAL NEURALGIA TREATMENT MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

Drug Based
Anticonvulsant Medicines
Tricyclic Antidepressants
Surgery
Radiofrequency Thermal Lesioning
Stereotactic Radiosurgery
Microvascular Decompression
Others

GLOBAL NEURALGIA TREATMENT MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032

Hospital & Clinics
Ambulatory Surgery Centers
Others

GLOBAL NEURALGIA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA Show more